Young adult (18-24-year-old) Black, Hispanic, and white men-who-have-sex-with-men (MSM) have among the highest incidences of new HIV infections in the US yet have low HIV testing rates. Access, cost, time, and concerns about confidentiality are some of the barriers that limit these men from being tested at traditional medical/community-based testing sites. A new US Food and Drug Administration-approved rapid HIV self-test (OraQuick® In-home HIV Test) might encourage and facilitate HIV testing because of its widespread access, convenience, ease of usage, oral fluid collection system, privacy, and rapid provision of test results. Despite these advantages, the investigators do not know if the new rapid HIV self-test will be preferred over medical/community-based or conventional "home-based" HIV testing, and if it will serve as a means of improving HIV testing use among young adult MSM.

The objectives of this study are to: (1) determine if testing uptake is higher in a rapid HIV self-testing group than in a conventional "home-based" HIV testing group and a community/medical-based testing referral group; (2) determine if time to initiation of HIV testing is shorter in the rapid HIV self-testing group, as compared to the other two participant groups; (3) determine if participants are more willing to contact and refer other young adult MSM to this study to use a rapid HIV self-test vs. a conventional "home-based" HIV test, or vs. a community/medical-based HIV test; (4) determine if those referred for rapid HIV self-testing are more likely to enroll in the study, have a higher uptake of testing, and have a shorter time to initiate HIV testing than those referred for conventional "home-based" HIV test, or a community/medical-based HIV test.

This study is comprised of three stages, the first of which is closed. In Stage I of this study, the investigators surveyed a large sample of MSM social-networking website users and assessed their acceptance, facilitators/barriers to use, utilization, preferences, and opinions regarding the new rapid HIV self-test, as compared to conventional "home-based" HIV testing or medical or community-based HIV testing. Of the participants enrolled in Stage I, 150 Black, 150 Hispanic, and 150 white MSM will be invited to participant in Stage II of this study. In this randomized, controlled trial, participants will be assigned to one of three HIV testing groups: (1) rapid HIV self-testing group (OraQuick® In-home HIV Test), (2) conventional "home-based" HIV testing group (Home Access Express), and (3) community/medical-based HIV testing group. Participants assigned to the rapid and conventional HIV testing groups will receive an internet-based coupon to order a free HIV testing kit from a specified pharmacy's website that will be delivered to the address of their choosing. The rapid HIV self-test kit and the conventional "home-based" HIV test kit contain all materials and instructions needed to conduct an HIV test. Participants assigned to the community/medical-based HIV testing group will receive a link to a CDC website (https://gettested.cdc.gov) that allows them to search for HIV testing locations of their choice. Participants in all three groups will receive an email explaining that the investigators are measuring uptake and time to testing among study participants. They will also be informed that the investigators will contact them after they have been tested to ask for their opinions regarding their testing experience. At the end of Stage II, participants will have the opportunity to refer other young adult MSM to the study via email. Referral participants will encompass Stage III of the study. Stage III participants will be assigned to the same testing group as the individual who referred them. Confidentiality will be maintained throughout all three stages of this study.